564 related articles for article (PubMed ID: 33999135)
21. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
Marietta M; Vandelli P; Mighali P; Vicini R; Coluccio V; D'Amico R;
Trials; 2020 Jun; 21(1):574. PubMed ID: 32586394
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial.
Audemard-Verger A; Le Gouge A; Pestre V; Courjon J; Langlois V; Vareil MO; Devaux M; Bienvenu B; Leroy V; Goulabchand R; Colombain L; Bigot A; Guimard T; Douadi Y; Urbanski G; Faucher JF; Maulin L; Lioger B; Talarmin JP; Groh M; Emmerich J; Deriaz S; Ferreira-Maldent N; Cook AR; Lengellé C; Bourgoin H; Mekinian A; Aouba A; Maillot F; Caille A
PLoS One; 2022; 17(8):e0269065. PubMed ID: 35925914
[TBL] [Abstract][Full Text] [Related]
23. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
[TBL] [Abstract][Full Text] [Related]
24. Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.
Putman M; Chock YPE; Tam H; Kim AHJ; Sattui SE; Berenbaum F; Danila MI; Korsten P; Sanchez-Alvarez C; Sparks JA; Coates LC; Palmerlee C; Peirce A; Jayatilleke A; Johnson SR; Kilian A; Liew J; Prokop LJ; Murad MH; Grainger R; Wallace ZS; Duarte-García A;
Arthritis Rheumatol; 2021 Jan; 73(1):36-47. PubMed ID: 32741139
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.
Shakoory B; Carcillo JA; Chatham WW; Amdur RL; Zhao H; Dinarello CA; Cron RQ; Opal SM
Crit Care Med; 2016 Feb; 44(2):275-81. PubMed ID: 26584195
[TBL] [Abstract][Full Text] [Related]
26. Current evidence on the use of anakinra in COVID-19.
Khani E; Shahrabi M; Rezaei H; Pourkarim F; Afsharirad H; Solduzian M
Int Immunopharmacol; 2022 Oct; 111():109075. PubMed ID: 35905562
[TBL] [Abstract][Full Text] [Related]
27. Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Stroehlein JK; Wallqvist J; Iannizzi C; Mikolajewska A; Metzendorf MI; Benstoem C; Meybohm P; Becker M; Skoetz N; Stegemann M; Piechotta V
Cochrane Database Syst Rev; 2021 May; 5(5):CD015043. PubMed ID: 34029377
[TBL] [Abstract][Full Text] [Related]
28. A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19.
Kharazmi AB; Moradi O; Haghighi M; Kouchek M; Manafi-Rasi A; Raoufi M; Shoaei SD; Hadavand F; Nabavi M; Miri MM; Salarian S; Shojaei S; Khalili S; Sistanizad M; Sadeghi S; Karagah A; Asgari S; Jaffaraghaei M; Araghi S
Immun Inflamm Dis; 2022 Feb; 10(2):201-208. PubMed ID: 34762351
[TBL] [Abstract][Full Text] [Related]
29. Anakinra for severe forms of COVID-19: a cohort study.
Huet T; Beaussier H; Voisin O; Jouveshomme S; Dauriat G; Lazareth I; Sacco E; Naccache JM; Bézie Y; Laplanche S; Le Berre A; Le Pavec J; Salmeron S; Emmerich J; Mourad JJ; Chatellier G; Hayem G
Lancet Rheumatol; 2020 Jul; 2(7):e393-e400. PubMed ID: 32835245
[TBL] [Abstract][Full Text] [Related]
30. The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A Systematic Review and Meta-Analysis.
Somagutta MKR; Lourdes Pormento MK; Hamid P; Hamdan A; Khan MA; Desir R; Vijayan R; Shirke S; Jeyakumar R; Dogar Z; Makkar SS; Guntipalli P; Ngardig NN; Nagineni MS; Paul T; Luvsannyam E; Riddick C; Sanchez-Gonzalez MA
Infect Chemother; 2021 Jun; 53(2):221-237. PubMed ID: 34216117
[TBL] [Abstract][Full Text] [Related]
31. Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study.
Küçükşahin O; Erden A; Karakaş Ö; Güven SC; Armağan B; Şahiner EŞ; İnan O; Kurtipek AC; Gemcioğlu E; Karaahmetoğlu S; Turan S; İzdeş S; Erdem D; Aypak A; Ayhan M; Akıncı E; Bodur H; Güner R; Omma A; Ateş İ
Turk J Med Sci; 2022 Oct; 52(5):1486-1494. PubMed ID: 36422492
[TBL] [Abstract][Full Text] [Related]
32. Anakinra was not associated with lower mortality in hospitalised COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.
Shang W; Zhang Y; Wang G; Han D
Rev Med Virol; 2023 Mar; 33(2):e2418. PubMed ID: 36600551
[TBL] [Abstract][Full Text] [Related]
33. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
[TBL] [Abstract][Full Text] [Related]
34. The Effect of Anakinra in Hospitalized Patients with COVID-19: An Updated Systematic Review and Meta-Analysis.
Kyriakoulis KG; Kollias A; Poulakou G; Kyriakoulis IG; Trontzas IP; Charpidou A; Syrigos K
J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640480
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
36. Spontaneous NLRP3 inflammasome-driven IL-1-β secretion is induced in severe COVID-19 patients and responds to anakinra treatment.
Bertoni A; Penco F; Mollica H; Bocca P; Prigione I; Corcione A; Cangelosi D; Schena F; Del Zotto G; Amaro A; Paladino N; Pontali E; Feasi M; Signa S; Bustaffa M; Caorsi R; Palmeri S; Contini P; De Palma R; Pfeffer U; Uva P; Rubartelli A; Gattorno M; Volpi S
J Allergy Clin Immunol; 2022 Oct; 150(4):796-805. PubMed ID: 35835255
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of anticytokine treatments added to corticosteroids in patients with COVID-19-associated pneumonia and hyperinflammation: a single center experience.
Yildirim F; Erdogan M; Mutlu MY; Icacan OC; Onar MI; Bes C
Eur Rev Med Pharmacol Sci; 2022 Oct; 26(19):7297-7304. PubMed ID: 36263542
[TBL] [Abstract][Full Text] [Related]
38. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
[TBL] [Abstract][Full Text] [Related]
39. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
40. Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study.
Borie R; Savale L; Dossier A; Ghosn J; Taillé C; Visseaux B; Jebreen K; Diallo A; Tesmoingt C; Morer L; Goletto T; Faucher N; Hajouji L; Neukirch C; Phillips M; Stelianides S; Bouadma L; Brosseau S; Ottaviani S; Pluvy J; Le Pluart D; Debray MP; Raynaud-Simon A; Descamps D; Khalil A; Timsit JF; Lescure FX; Descamps V; Papo T; Humbert M; Crestani B; Dieude P; Vicaut E; Zalcman G;
PLoS One; 2020; 15(12):e0243961. PubMed ID: 33326457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
